Editas Medicine Inc banner

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 2.59 USD -0.77%
Market Cap: $253.5m

Multiples-Based Value

The Multiples-Based Value for Editas Medicine Inc (EDIT) under the Base Case is hidden USD. Compared with the current market price of 2.59 USD, the stock appears hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EDIT Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

EDIT Competitors Multiples
Editas Medicine Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Editas Medicine Inc
NASDAQ:EDIT
255.4m USD 6.3 -1.6 -1.7 -1.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
380.1B USD 6.1 88.5 14.7 20.4
US
Amgen Inc
NASDAQ:AMGN
190.4B USD 5.1 24.3 14.1 14.1
US
Gilead Sciences Inc
NASDAQ:GILD
174.1B USD 5.9 20.4 12.7 15.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD 9.3 28.2 21.2 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.2B USD 5.5 17.6 13 14.8
AU
CSL Ltd
ASX:CSL
68.5B AUD 3.1 34 11.3 14.2
NL
argenx SE
XBRU:ARGX
39.5B EUR 11.3 36.2 39.3 40.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average P/S: 3 063 003.3
6.3
-33%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.3
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
NL
argenx SE
XBRU:ARGX
11.3
27%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Editas Medicine Inc
NASDAQ:EDIT
Average P/E: 35.6
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.5
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.3
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.4
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
13%
1.4
AU
CSL Ltd
ASX:CSL
34
10%
3.4
NL
argenx SE
XBRU:ARGX
36.2
32%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average EV/EBITDA: 18
Negative Multiple: -1.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.7
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.1
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
18%
0.7
AU
CSL Ltd
ASX:CSL
11.3
7%
1.6
NL
argenx SE
XBRU:ARGX
39.3
50%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Editas Medicine Inc
NASDAQ:EDIT
Average EV/EBIT: 20.2
Negative Multiple: -1.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.4
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.1
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.7
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
23%
0.6
AU
CSL Ltd
ASX:CSL
14.2
10%
1.4
NL
argenx SE
XBRU:ARGX
40.1
51%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett